Your browser doesn't support javascript.
loading
Interaction of Avibactam with Class B Metallo-ß-Lactamases.
Abboud, Martine I; Damblon, Christian; Brem, Jürgen; Smargiasso, Nicolas; Mercuri, Paola; Gilbert, Bernard; Rydzik, Anna M; Claridge, Timothy D W; Schofield, Christopher J; Frère, Jean-Marie.
Afiliação
  • Abboud MI; Department of Chemistry, University of Oxford, Oxford, United Kingdom.
  • Damblon C; Laboratoire de Chimie Biologique Structurale (CBS), Département de Chimie, Université de Liège, Liège, Belgium.
  • Brem J; Department of Chemistry, University of Oxford, Oxford, United Kingdom.
  • Smargiasso N; Laboratory of Mass Spectrometry, GIGA-R-CART, Université de Liège, Liège, Belgium.
  • Mercuri P; Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium.
  • Gilbert B; Chimie Analytique Inorganique, Département de Chimie, Université de Liège, Liège, Belgium.
  • Rydzik AM; Department of Chemistry, University of Oxford, Oxford, United Kingdom.
  • Claridge TD; Department of Chemistry, University of Oxford, Oxford, United Kingdom.
  • Schofield CJ; Department of Chemistry, University of Oxford, Oxford, United Kingdom christopher.schofield@chem.ox.ac.uk jmfrere@ulg.ac.be.
  • Frère JM; Centre d'Ingénierie des Protéines, Université de Liège, Liège, Belgium christopher.schofield@chem.ox.ac.uk jmfrere@ulg.ac.be.
Antimicrob Agents Chemother ; 60(10): 5655-62, 2016 10.
Article em En | MEDLINE | ID: mdl-27401561
ABSTRACT
ß-Lactamases are the most important mechanisms of resistance to the ß-lactam antibacterials. There are two mechanistic classes of ß-lactamases the serine ß-lactamases (SBLs) and the zinc-dependent metallo-ß-lactamases (MBLs). Avibactam, the first clinically useful non-ß-lactam ß-lactamase inhibitor, is a broad-spectrum SBL inhibitor, which is used in combination with a cephalosporin antibiotic (ceftazidime). There are multiple reports on the interaction of avibactam with SBLs but few such studies with MBLs. We report biochemical and biophysical studies on the binding and reactivity of avibactam with representatives from all 3 MBL subfamilies (B1, B2, and B3). Avibactam has only limited or no activity versus MBL-mediated resistance in pathogens. Avibactam does not inhibit MBLs and binds only weakly to most of the MBLs tested; in some cases, avibactam undergoes slow hydrolysis of one of its urea N-CO bonds followed by loss of CO2, in a process different from that observed with the SBLs studied. The results suggest that while the evolution of MBLs that more efficiently catalyze avibactam hydrolysis should be anticipated, pursuing the development of dual-action SBL and MBL inhibitors based on the diazabicyclooctane core of avibactam may be productive.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Beta-Lactamases / Compostos Azabicíclicos / Inibidores de beta-Lactamases Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Beta-Lactamases / Compostos Azabicíclicos / Inibidores de beta-Lactamases Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido